Nektar Therapeutics (NASDAQ:NKTR) is one of the best hot stocks to buy according to Wall Street analysts. On June 24, Nektar ...

A new immune-modulating treatment has shown promising results for treating moderate to severe eczema, delivering fast itch ...

Nektar, which accused Lilly of making errors in its analysis of the data, forged ahead with the programme and started the ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, ...

Nektar Therapeutics (NKTR) is headed for its best day since August 2023 after positive trial results for its eczema drug ...

Nektar Therapeutics’ biologic drug rezpegaldesleukin take a new approach to atopic dermatitis, or eczema, stimulating proliferation of immune cells that tamp down excessive immune responses. The ...

Nektar Therapeutics said on Tuesday its experimental eczema drug had met the main goal of a mid-stage study, sending its shares up by more than 140% in premarket trading. In the 393-patient trial, ...

Nektar Therapeutics said on Tuesday its experimental eczema drug had met the main goal of a mid-stage study. In the 393-patient trial, drug candidate rezpegaldesleukin showed a reduction in the ...

Learn how Dupixent helps diverse eczema patients and why inclusive clinical trials are vital for fair healthcare.

The agency said it will evaluate whether regulatory action is needed after investigating the deaths of two patients treated ...

Researchers at Brown University’s School of Public Health found that children exposed to higher levels of triclosan may be ...